新里程健康科技集团股份有限公司2024年半年度非经营性资金占用及其他关联资金往来情况汇总表 | 编制单位：新里程健康科技集团股份有限公司 | | | | | | | | | 金额单位：人民币万元 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 非经营性资金占用 | | 资金占用方名称 占用方与上市公司的 | 上市公司核算的会 | 2024年期初占用资 | 2024年半年度占用累计发生 | 2024年半年度占用资金 | 2024年半年度偿还 | 2024年半年度末占 | 占用形成原因 | 占用性质 | | | | 关联关系 | 计科目 | 金余额 | 金额（不含利息） | 的利息（如有） | 累计发生金额 | 用资金余额 | | | | 控股股东、实际控制人及其附属企业 | | | | | | | | | | 非经营性占用 | | 小 计 | - | - | - | | | | | | | - | | 前控股股东、实际控制人及其附属企业 | | | | | | | | | | 非经营性占用 | | 小 计 | - ...

Financial Performance - The company's operating revenue for the reporting period was CNY 1,820,242,878.06, representing a 12.20% increase compared to the previous year's CNY 1,606,723,364.98[11] - The net profit attributable to shareholders of the listed company was CNY 60,144,512.50, which is a 5.27% increase from CNY 57,004,556.73 in the same period last year[11] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 58,555,051.85, marking an 18.46% increase from CNY 49,304,434.47 in the previous year[11] - The net cash flow from operating activities was CNY 144,585,899.24, up 15.50% from CNY 125,210,313.12 in the same period last year[11] - The company achieved a consolidated revenue of CNY 1.82 billion in the first half of 2024, representing a year-on-year growth of 12.20%[21] - The net profit for the period was CNY 62.31 million, with a net profit attributable to shareholders of CNY 60.14 million, reflecting a year-on-year growth of 5.27%[21] Assets and Liabilities - The total assets at the end of the reporting period were CNY 6,304,292,218.43, reflecting a 3.69% increase from CNY 6,080,204,990.53 at the end of the previous year[11] - The net assets attributable to shareholders of the listed company were CNY 2,306,984,135.12, which is a 5.07% increase from CNY 2,195,689,411.03 at the end of the previous year[11] - The asset-liability ratio decreased to 62.77%, down by 0.48 percentage points from the beginning of the year[21] - The company's total liabilities amounted to CNY 3,957,348,044.19, up from CNY 3,845,698,741.33, showing an increase of around 2.9%[71] Earnings and Shareholder Returns - The basic earnings per share for the reporting period was CNY 0.0176, a 2.92% increase from CNY 0.0171 in the same period last year[11] - The diluted earnings per share also stood at CNY 0.0176, reflecting the same 2.92% increase as the basic earnings per share[11] - The company plans not to distribute cash dividends or bonus shares for this reporting period[1] - The company plans not to distribute cash dividends or bonus shares for the first half of 2024[37] Market and Business Strategy - The company aims to enhance its market share and operational quality through strategic restructuring and scale expansion in its medical services business[16] - The company is focused on addressing the growing demand for healthcare services driven by an aging population and increasing chronic disease prevalence[17] - The company is actively expanding its market presence in the pharmaceutical sector, particularly in traditional Chinese medicine, and is exploring new business opportunities[21] - The company is focusing on a dual-driven strategy of "medical + pharmaceutical," with a clear direction for its subsidiaries in both sectors[21] Operational Developments - The company has established five regional medical centers in Liaoning, Henan, Jiangsu, Jiangxi, and Sichuan, with a total of 3 tertiary hospitals and 7 secondary hospitals[14] - The company added 6 new provincial and municipal key specialties during the reporting period, enhancing its medical service capabilities[21] - The company has implemented a refined management approach to enhance operational efficiency and service quality across its hospitals[21] Research and Development - The company is developing a new oral care product line leveraging the medicinal properties of its "Duyiwei" products, aiming to enter the fast-moving consumer goods market[16] - Research and development expenses increased significantly to ¥6,403,898.44, compared to ¥818,986.75 in the previous year, marking an increase of 681.5%[78] - The company plans to enhance its research and development efforts to innovate new technologies[97] Shareholder Structure and Governance - The company held its first extraordinary general meeting of 2024 on March 11, with a participation rate of 33.06%[34] - The annual general meeting on May 10, 2024, had a participation rate of 32.42%[34] - The company elected new directors, including Xue Ping as a non-independent director on March 11, 2024[36] - The company has implemented a stock incentive plan to attract and retain talent, aligning interests among shareholders, the company, and employees[38] Financial Management and Risks - The company faces risks related to policy changes in the healthcare sector, which may impact operations and profitability[32] - The company has assessed its ability to continue as a going concern for the next 12 months, indicating sufficient resources to maintain operations[110] - The company has a structured approach to accounting for lease payments, ensuring compliance with relevant accounting standards[171] Accounts Receivable and Bad Debts - Accounts receivable increased to ¥1,253,725,754.16, accounting for 19.89% of total assets, up by 3.06% from the previous year[27] - The total accounts receivable at the end of the period amounted to ¥1,585,619,180.08, with a bad debt provision of ¥331,893,425.92, resulting in a provision ratio of 20.92%[194] - The company has identified multiple accounts with a 100% expected unrecoverability rate, indicating a high risk of default across its receivables[193] Environmental and Legal Compliance - The company has not faced any administrative penalties related to environmental issues during the reporting period and complies with various environmental protection laws[43] - There were no significant lawsuits or arbitration matters during the reporting period, indicating a stable legal environment for the company[47] - The company has not engaged in any major related party transactions or non-operating fund occupation by controlling shareholders during the reporting period[47]

新里程健康科技集团股份有限公司 证券简称：新里程 证券代码：002219 公告编号：2024-071 新里程健康科技集团股份有限公司 关于控股股东部分股份解除质押及再质押的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏。 新里程健康科技集团股份有限公司（以下简称"新里程"或"公司"）近日 接到公司控股股东北京新里程健康产业集团有限公司（以下简称"新里程集团" 或"控股股东"）函告并通过中国证券登记结算有限公司系统查询，获悉其所持 有本公司的部分股份解除质押及再质押，具体事项如下： 2．股东股份累计质押情况 截至公告披露日，控股股东所持质押股份情况如下： | 股东 | 是否为 控股股 | 本次解除质 押股份数量 | 占其所 持股份 | 占公司总 | 质押起 | 解除 | 质权人 | | --- | --- | --- | --- | --- | --- | --- | --- | | 名称 | | | | 股本比例 | 始日 | 日期 | | | | 东 | (股) | 比例 | | | | | | 新里程 | | 157,480,315 | 19.07% | ...

北京市中伦律师事务所 关于新里程健康科技集团股份有限公司 2024 年第四次临时股东大会的 法律意见书 二〇二四年八月 北京市中伦律师事务所 关于新里程健康科技集团股份有限公司 2024 年第四次临时股东大会的 法律意见书 致：新里程健康科技集团股份有限公司 北京市中伦律师事务所（以下简称"本所"）受新里程健康科技集团股份有 限公司（以下简称"公司"）委托，指派律师出席公司 2024 年第四次临时股东 大会（以下简称"本次股东大会"）。本所律师根据《中华人民共和国公司法》 （以下简称"《公司法》"）、《上市公司股东大会规则》等相关法律、法规、 规范性文件及《新里程健康科技集团股份有限公司章程》（以下简称"《公司章 程》"）、《新里程健康科技集团股份有限公司股东大会议事规则》（以下简称 "《股东大会规则》"）的规定，对本次股东大会进行见证并出具法律意见。 经查验，根据公司第六届董事会第二十四次会议的决议，公司于 2024 年 8 月 2 日在指定媒体发布了《新里程健康科技集团股份有限公司关于召开 2024 年 第四次临时股东大会的通知》（以下简称"《会议通知》"）。本次会议由公司 董事会召集，《会议通知》的内容 ...

证券简称：新里程 证券代码：002219 公告编号：2024-070 新里程健康科技集团股份有限公司 公司已在中国证券登记结算有限责任公司深圳分公司开立了回购专用证券 账户，该账户仅用于回购公司股份。 新里程健康科技集团股份有限公司 回购股份报告书 新里程健康科技集团股份有限公司（以下简称"公司"）拟使用自有或自筹 资金以集中竞价交易方式回购公司已发行的人民币普通股（A 股）股票，回购股 份价格不超过人民币 2.74 元/股（含），本次拟回购金额不低于人民币 5,000 万 元（含），不超过人民币 10,000 万元（含），预计回购股份数量约为 18,248,175 股至 36,496,350 股，约占公司目前已发行总股本比例为 0.54%至 1.07%。本次回 购股份为维护公司价值及股东权益所必需，本次股份回购后拟全部用于减少注册 资本。本次回购股份的实施期限自股东大会审议通过回购股份方案之日起不超过 三个月。具体回购资金总额和数量以回购期限届满或回购实施完成时实际回购使 用的资金总额和股份数量为准。 本公司董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 2、回购股 ...

新里程健康科技集团股份有限公司 证券简称：新里程 证券代码：002219 公告编号：2024-068 新里程健康科技集团股份有限公司 2024年第四次临时股东大会决议公告 特别提示： 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 1、本次股东大会无否决提案的情形。 2、本次股东大会无涉及变更以往股东大会已通过的决议。 一、会议召开和出席情况 （一）会议召开情况 1、会议召开时间 （1）现场会议时间：2024年8月19日（星期一）下午14:50开始 （2）网络投票时间：2024 年 8 月 19 日 其中，通过深圳证券交易所交易系统进行网络投票的时间为：2024 年 8 月 19 日 9:15-9:25，9:30-11:30 和 13:00-15:00；通过深圳证券交易所互联网投票系 统进行网络投票的时间为：2024 年 8 月 19 日 9:15 至 15:00 期间的任意时间。 2、会议召开地点：北京市朝阳区东三环中路5号财富金融中心29层。 5、现场会议主持人：董事长林杨林先生 6、本次股东大会的召集、召开及表决程序符合《公司法》《上市公司股东 大会规则》《 ...

新里程健康科技集团股份有限公司 证券简称：新里程 证券代码：002219 公告编号：2024-069 新里程健康科技集团股份有限公司 关于注销回购股份减少注册资本暨通知债权人的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏。 一、通知债权人的原因 新里程健康科技集团股份有限公司（以下简称"新里程"或"公司"）于 2024 年 8 月 1 日召开第六届董事会第二十四次会议、第六届监事会第十八次会 议，于 2024 年 8 月 19 日召开 2024 年第四次临时股东大会，审议通过了《关于 回购公司股份并减资注销方案的议案》。为维护公司价值及股东权益所必需，公 司拟使用自有或自筹资金以集中竞价交易方式回购公司部分股份，本次股份回购 后拟全部用于减少注册资本，具体内容详见公司 2024 年 8 月 2 日刊载于《证券 时报》《证券日报》《上海证券报》《中国证券报》和巨潮资讯网（www.cninfo.com.cn） 的《关于回购公司股份并减资注销的方案》（公告编号：2024-064）。 根据本次回购方案，公司自股东大会审议通过之日起 3 个月内使用自有资金 人民币不低 ...

本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 新里程健康科技集团股份有限公司 证券简称：新里程 证券代码：002219 公告编号：2024-067 新里程健康科技集团股份有限公司 关于回购股份事项前十名股东和前十名无限售条件股东 持股情况的公告 中国证券登记结算有限责任公司深圳分公司出具的股东名册。 特此公告。 新里程健康科技集团股份有限公司（以下简称"新里程"或"公司"）于 2024 年 8 月 1 日召开第六届董事会第二十四次会议、第六届监事会第十八次会议审议 通过了《关于回购公司股份并减资注销方案的议案》，并定于 2024 年 8 月 19 日 召开 2024 年第四次临时股东大会审议上述议案，具体内容详见公司 2024 年 8 月 2 日登载于《证券时报》《证券日报》《中国证券报》《上海证券报》和巨潮资 讯网（www.cninfo.com.cn）的《关于回购公司股份并减资注销的方案》及《关于 召开 2024 年第四次临时股东大会的通知》。 根据《深圳证券交易所上市公司自律监管指引第 9 号——回购股份（2023 年修订）》的相关规定，现将公司 2024 ...

Investment Rating - The report assigns a "Buy" rating for the company [1][3]. Core Views - The company is demonstrating confidence in its future development through a share buyback plan, intending to repurchase shares at a price not exceeding RMB 2.74 per share, with a total value between RMB 50 million to 100 million [1]. - The medical services segment is showing steady growth, with Q1 2024 revenue reaching RMB 740 million, a year-on-year increase of 5.62% [2][3]. - The company is actively expanding its hospital network, with new facilities expected to enhance bed utilization rates and overall revenue [2][3]. - The pharmaceutical segment is also performing well, with a 45.24% increase in revenue to RMB 121 million in Q1 2024, driven by strategic acquisitions [2][3]. Summary by Sections Company Overview - The latest closing price is RMB 2.24, with a one-year high of RMB 3.90 and a low of RMB 1.66 [2]. - The current price-to-earnings (PE) ratio is 228.40, and the price-to-book (PB) ratio is 3.40 [2]. Financial Performance - Revenue projections for 2024 to 2026 are RMB 4.006 billion, RMB 4.484 billion, and RMB 5.004 billion, with year-on-year growth rates of 11.6%, 11.9%, and 11.6% respectively [3]. - The net profit attributable to the parent company is expected to rise significantly, from RMB 143 million in 2024 to RMB 350 million in 2026, reflecting growth rates of 362.7%, 78.5%, and 37.5% [3]. - Earnings per share (EPS) is projected to increase from RMB 0.04 in 2024 to RMB 0.10 in 2026 [3]. Business Segments - The medical services segment is expected to benefit from both organic growth and external expansion, with ongoing projects to increase hospital capacity [2][3]. - The pharmaceutical segment is leveraging acquisitions to enhance its market position and revenue potential [2][3].

Investment Rating - The report assigns a "Buy" rating to the company [1] Core Views - The company plans to repurchase shares at a price not exceeding RMB 2 74 per share with a total amount ranging from RMB 50 million to RMB 100 million The repurchased shares will be used to reduce registered capital [1] - The healthcare services sector has shown steady growth with a 5 62% increase in revenue to RMB 740 million in Q1 2024 New hospital constructions are progressing well with several projects expected to be operational by the end of 2024 [3] - The company's pharmaceutical sector achieved a 45 24% increase in revenue to RMB 121 million in Q1 2024 driven by the acquisition of Gansu Furen Pharmaceutical and the exploration of the "Duyiwei" brand's potential in the consumer market [3] - The company's share repurchase demonstrates confidence in future development and is expected to enhance earnings per share and shareholder returns [3] Financial Projections - Revenue is projected to grow from RMB 40 06 billion in 2024 to RMB 50 04 billion in 2026 with a compound annual growth rate (CAGR) of 11 6% [3] - Net profit attributable to the parent company is expected to increase significantly from RMB 143 million in 2024 to RMB 350 million in 2026 with growth rates of 362 7% 78 5% and 37 5% respectively [3] - The company's PE ratio is forecasted to decrease from 53 7 in 2024 to 21 9 in 2026 indicating improving valuation metrics [3] Business Development - The healthcare services sector is expected to benefit from both organic growth and external expansion The company is actively pursuing asset injections and has submitted materials to the Shenzhen Stock Exchange for a private placement [3] - The company's controlling shareholder manages nearly 30 secondary and above hospitals nationwide with a total of 20 000 beds which is approximately twice the scale of the listed company's assets [3] Financial Ratios - The company's gross margin is expected to improve from 30 1% in 2023 to 35 6% in 2026 while the net margin is projected to increase from 1 1% to 7 3% over the same period [4] - ROE is forecasted to rise from 1 4% in 2023 to 8 4% in 2026 reflecting enhanced profitability and efficiency [4]